A headline asks whether an earnings beat changed the investment story for Regeneron Pharmaceuticals. But the supplied facts don’t include the earnings figures needed to assess that claim.
The October 16 headline, “Did Earnings Beat Just Shift Regeneron Stock Investment Narrative?”, puts the beat at the centre of the story. An October 15 headline also describes an earnings beat, but no reported results, analyst estimates, or size of the beat are provided. Regeneron’s latest listed close was US$803.01, up 2.31% for the day.
Investor takeaway: The headlines identify an earnings beat as the catalyst. Without the results or a comparison with expectations, its effect on Regeneron’s business outlook is unclear.
Advertisement
Regeneron Pharmaceuticals Inc
REGN.US
REGN.US
Regeneron Pharmaceuticals Inc
WealthAwesomeMarket cap
$80.14B
P/E
18.6x
Div. yield
0.48%
Div. / share
$3.64
52W high
$859.34
52W low
$569.83
1W change
+7.68%
Beta
0.15
Analyst Price Targets
Based on 27 analysts covering REGN · as of Oct 14, 2026
Wall Street analysts forecast REGN stock price to rise 8.0% over the next 12 months.
Consensus
Buy4.15 / 5.00
Avg. Target
C$859.69
+8.0% Upside
Previously C$859.04 on Oct 12, 2026
Current Price
C$796.34
Last close
Analyst Breakdown (27 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on REGN's historical volatility
30-Day Vol
28.1%
Annualized
90-Day Vol
29.2%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$952.03
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$845.18 | C$766.98 – C$931.36 |
| 60 trading days | C$897.02 | C$781.93 – C$1029.04 |
| 90 trading days | C$952.03 | C$804.67 – C$1126.38 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
US$803.01 close; earnings figures not supplied
Regeneron closed at US$803.01, up 2.31% for the day. Latest volume was 24,638 shares, compared with a reported 20-day average of 794,995 shares. The supplied volume comparison is 1.00x.
Bull case
The supplied headlines report an earnings beat, and Regeneron’s listed one-day and one-week returns were positive.
Bear case
The supplied information includes no earnings figures, guidance, or details about the beat. Its size and staying power are therefore unclear.
What happened: an earnings beat is the stated catalyst
Advertisement
The October 16 end-of-day headline asks whether an earnings beat changed Regeneron’s investment narrative. An October 15 company-news headline also says the stock rallied on an earnings beat. These headlines identify the event, but the supplied facts don’t include revenue, earnings per share, analyst expectations, or how much results exceeded expectations. There’s also no management commentary or updated guidance. The event is clear; the details behind it are not. Visit the REGN.US stock page.
What the numbers show: a US$803.01 close
Regeneron’s latest close was US$803.01, up 2.31% for the day and 7.68% for the week. The supplied one-month return was 2.87%, and the year-to-date return was 2.98%. Latest volume was 24,638 shares, compared with a reported 20-day average of 794,995 shares. The listed volume-versus-average figure was 1.00x. The supplied facts don’t explain how that figure relates to the latest volume, so it shouldn’t be used to infer unusual trading activity. Regeneron’s listed market capitalization was US$80,136,044,544, and its P/E was 18.6211. These figures provide context but don’t explain what drove the earnings beat. Find more company information on the Regeneron stock page.
What to watch next: the missing earnings details
The next details to look for are the actual results, the expectations they beat, and any guidance or business updates released with the report. None appears in the supplied facts, so it’s not possible to tell whether the beat reflects broad improvement or a narrower result. The October 15 headlines about valuation and trial data are separate stories. They don’t provide the missing earnings figures and shouldn’t be treated as evidence explaining the beat.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
